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While antibodies currently play a dominant role as affinity reagents in biological research and for
diagnostics, a broad range of recombinant proteins are emerging as promising alternative affinity
reagents in detection assays and quantification. DNA-mediated affinity-based assays, such as immuno-
PCR and proximity ligation assays (PLA), use oligonucleotides attached to affinity reagents as reporter
molecules. Conjugation of oligonucleotides to affinity reagents generally employs chemistries that
target primary amines or cysteines. Because of the random nature of these processes neither the number
of oligonucleotides conjugated per molecule nor their sites of attachment can be accurately controlled
for affinity reagents with several available amines and cysteines. Here, we present a straightforward and
convenient approach to functionalize recombinant affinity reagents for PLA by expressing the reagents
as fusion partners with SNAP protein tags. This allowed us to conjugate oligonucleotides in a site-specific
fashion, yielding precisely one oligonucleotide per affinity reagent. We demonstrate this method using
designed ankyrin repeat proteins (DARPins) recognizing the tumor antigen HER2 and we apply the
conjugates in different assay formats. We also show that SNAP or CLIP tags, expressed as fusion partners
of transfected genes, allow oligonucleotide conjugations to be performed in fixed cells, with no need for
specific affinity reagents. The approach is used to demonstrate induced interactions between the fusion
proteins FKBP and FRB by allowing the in situ conjugated oligonucleotides to direct the production of
templates for localized rolling circle amplification reactions.Introduction
For biomedical research and diagnostics, there is a need for
standardized high-performance assays to analyze proteins and
their interactions and modifications in situ, in cell lysates, or in
body fluids. Such assays are likely to play increasing roles in
medical practice by revealing diagnostic protein patterns, and
supporting the selection of optimal therapy. These applicationsCorresponding author: So¨derberg, O. (ola.soderberg@igp.uu.se)
4 These authors contributed equally to the work.
144 www.elsevier.com/locate/nbt 1871-6784/$ - see front mwill require high-performance protein assays and broadly avail-
able repertoires of well-characterized affinity reagents for proteins
of interest [1].
Currently, polyclonal or monoclonal antibodies are used in
most affinity-based protein analyses, but several classes of recom-
binant affinity reagents are under development such as nanobo-
dies [2], affibody [3], DARPins and others [4–6]. Such reagents can
offer important advantages in terms of engineered specificity and
affinity, and also in production. Because of properties such as
excellent stability, small size and the possibility to engineer thematter  2012 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.nbt.2012.05.005
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extend the range of applications of affinity reactions beyond those
of antibodies. Examples of recombinant affinity reagents include
molecules that represent fragments of antibodies and a range of
scaffold proteins designed to exhibit contact surfaces that can be
varied for binding to putative target proteins [4,5]. A scaffold
protein with attractive properties for high-affinity protein binding
is the designed ankyrin repeat proteins (DARPins) [6]. These are
approximately 15–20 kDa in size (compared to 150 kDa for intact
IgG antibodies) and they exhibit impressive stability, surviving for
months at 378C. Because the DARPins have no cysteines and fold
well in the cytoplasm, they can also be expressed within the cell. A
repertoire of DARPins directed against extracellular and intracel-
lular target proteins is now available [6], and a particular effort has
been devoted to generating DARPins against the ErbB receptor
family, with affinities in the low nM to pM range [7–9].
Proximity ligation assay (PLA) can provide improved opportu-
nities for measuring proteins [10] or more complex targets such as
interacting or aggregated proteins [11] and exosomes [12] in blood
samples and cell lysates [13]. The technique can also be applied to
visualize endogenous protein interactions [14–16] and post-transla-
tional modifications [17] in cells and tissues. Detection of proteins
or protein complexes using PLA requires binding by two or moreFIGURE 1
Schematic illustration of in situ PLA and solid-phase PLA using DARPin PLA probes. (
by two DARPin PLA probes to which oligonucleotides (priming (with arrow) and non
are then hybridized to PLA probes in close proximity and enzymatically ligated to fo
PLA probes serving as a primer, forming an RCA product. Fluorophore-labeled dete
rolling circle products, resulting in bright sub-micrometer-sized DNA bundles. (B) In
specific antibody-coated solid phase. Upon simultaneous recognition of the targe
brought in close proximity and can be joined by enzymatic ligation in the presen
oligonucleotides. A DNA template is generated that can be exponentially amplifiaffinity reagents that are equipped with DNA oligonucleotides, and
referred to as PLA probes. Upon proximal binding by a set of PLA
probes amplifiable DNA strands, representative of proximal binding
events, are formed by DNA ligation. The reaction provides high
selectivity due to the requirement for multiple recognitions and
good sensitivity of detection is ensured via amplified detection. For
localized detection using in situ PLA, the DNA strands (priming and
non-priming) coupled to affinity reagents serve first as templates for
ligation, creating circular DNA molecules and then the priming acts
as primer for localized amplification via rolling circle amplification
(RCA) to form RCA products, containing hundreds copies of the
same oligonucleotide sequence. The RCA products are easily
detected as bright fluorescent spots using fluorophore-labeled hybri-
dization probes (Fig. 1A). These spots can then be digitally recorded
using dedicated software [18]. Real-time PCR is generally used to
measure ligation products representing proteins detected in solu-
tion phase such as in cell lysates (Fig. 1B).
The first demonstration of PLA reactions made use of DNA
aptamers as affinity reagents for the targeted proteins [10], but
in subsequent work poly- or monoclonal antibodies have generally
been used. Several different chemistries are available to conjugate
DNA strands to proteins. For antibodies, random coupling of
oligonucleotides to primary amines is most commonly usedA) In in situ PLA, targeted proteins or protein pairs are simultaneously bound
-priming (without arrow)) have been attached; circularization oligonucleotides
rm amplifiable DNA circles. The circularized DNA is replicated with one of the
ction oligonucleotides are then hybridized to the repeated sequence of the
 solid-phase PLA a sample (in this case cell lysate) is incubated with a target-
t protein by a pair of DARPin PLA probes, the attached oligonucleotides are
ce of a connector oligonucleotide complementary to the free ends of the
ed and quantified by quantitative PCR.
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reagents is relatively straightforward, but the process is poorly
defined and target binding may be affected. It is therefore desirable
to conjugate oligonucleotides in a site-directed fashion and pre-
ferably in a one-to-one ratio. For small proteins, where a significant
fraction of the surface is potentially involved in binding to the
target, random coupling of oligonucleotides is unsuitable. For
DARPins, protocols have been reported for stoichiometric site-
specific coupling of ligands such as polyethylene glycol (PEG) and
fluorophore at the N-terminal amino group, at engineered
cysteines or at modified amino acids capable of undergoing click
chemistry [20]. These reactions require purification of the ligand
(here an oligonucleotide) and the protein, as well as some con-
siderations about buffer and reaction conditions. For high-
throughput protein–oligonucleotide couplings, alternative strate-
gies with lower demands on reagent purity are thus of interest. A
mutant form of the human DNA repair protein O6-alkylguanine-
DNA alkyltransferase reacts rapidly and specifically with O6-ben-
zylguanine (BG) and also with derivatives that carry a large moiety
linked to the benzyl group [21]. With guanine as the leaving group,
the benzyl moiety becomes covalently attached to a cysteine in the
active site of the enzyme. The enzyme has also been mutagenized
to become specific for O6-benzylcytosine (BC) in a similar manner
[22]. Both enzyme domains (about 20 kDa) are commercially
available as SNAP and CLIP tags, respectively [22–24].
Here we have investigated the coupling of BG-modified DNA
oligonucleotides to DARPin-SNAP fusion proteins. Using anti-
HER2 DARPins [7–9] as a test case the resulting PLA probes were
validated by visualizing expression and interactions of endogen-
ous HER2 proteins in cells, and by measuring HER2 levels in cell
lysates. Furthermore, we illustrated the possibility to demonstrate
protein interactions in situ using BG- and BC-modified DNA oli-
gonucleotides as probes for in situ PLA detection of SNAP or CLIP
fusion proteins, expressed in transfected cells. The transfected cells
were fixed and permeabilized and interactions were analyzed by
adding BG- and BC-modified DNA oligonucleotides as PLA probes.
The oligonucleotides coupled in situ guided the circularization ofTABLE 1
Oligonucleotide sequences
Name Sequence 
Priming AAAAAAAAAAGACGCTAATAGTTAAGACGCT
Non-priming AAAAAAAAAATATGACAGAACTAGACACTCT
Circularization
oligonucleotide 1
CTATTAGCGTCCAGTGAATGCGAGTCCGTCTA
GAGAGTAGTACAGCAGCCGTCAAGAGTGTCT
Circularization
oligonucleotide 2
GTTCTGTCATATTTAAGCGTCTTAA 
Detection oligonucleotide CAGTGAATGCGAGTCCGTCT 
Biovic 1 CGCATCGCCCTTGGACTACGACTGACGAACC
CTTTGCCTGACTGATCGCTAAATCGTG
Biovic 2 TCGTGTCTAAAGTCCGTTACCTTGATTCCCCTA
ACCCTCTTGAAAAATTCGGCATCGGTGA
Fwdprimer CATCGCCCTTGGACTACGA 
Revprimer GGGAATCAAGGTAACGGACTTTAG 
Connector TACTTAGACACGACACGATTTAGTTT 
Taqman probe TGACGAACCGCTTTGCCTGA 
146 www.elsevier.com/locate/nbttwo other DNA strands that were then amplified by RCA and
visualized via hybridization of fluorophore-labeled oligonucleo-
tides. We show that this form of in situ PLA could successfully
demonstrate induced interactions between FKBP and FRB proteins
fused to SNAP- and CLIP-domains, respectively, with no need for
specific affinity reagents.
Materials and methods
Cloning, expression and purification of DARPin-SNAP fusion
proteins
The ORFs for the anti-HER2 DARPins 9.01 [8] and G3 [7] were
digested with BamHI and HindIII (New England Biolabs, Ipswich,
MA) and ligated into the compatible expression vectors pQiBi_11_S-
NAP or pQiBi_SNAP_11, which had been constructed by inserting
the SNAP domain into vectors made for creating DARPin fusion
proteins [9] (C. Gehringer et al., unpublished). This encodes
DARPins N- or C-terminally fused to the SNAP-tag via an (G4S)2-
linker. Fusion proteins were overexpressed in Escherichia coli XL1-
Blue and purified via their N-terminal MRGSH6 tag with nickel-
nitrilotriacetic acid superflow resin (Qiagen, Hilden, Germany)
giving yields of 25–40 mg of purified protein per liter expression
culture [7,8].
Plasmid construction of FKBP-SNAP and FRB-CLIP gene fusion
constructs
Gene construct encoding a fusion protein of FKBP (FK506-binding
protein) and the SNAP-tag, or construct encoding a fusion protein
of FRB (FKBP12/rapamycin-binding domain) and the CLIP-tag
were each cloned in a pNuc vectors as previously described [25],
hereafter, referred to as FKBP-SNAP and FRB-CLIP. To identify
transfected cells, a GFP-encoding vector, the pLPS-AcGFP1-N vec-
tor (Cat. No. 632472; Clontech), was co-transfected with the FKBP-
SNAP and FRB-CLIP gene fusion constructs.
Preparation of PLA probes
50 mL of 100 mM aldehyde-modified oligonucleotides (priming, non-
priming, biovic 1 and biovic 2, Table 1) were incubated for 3 hours atModification Company
T 50-Aldehyde, or 50-thiol Trilink Biotechnology
T 50-Aldehyde Trilink Biotechnology
A-
A
50-Phosphate Integrated DNA Technology
50-Phosphate Integrated DNA Technology
50-Alexa fluor 555 Trilink Biotechnology
G- 50-Aldehyde Eurogentec
- 50-Phosphate, 30-aldehyde Eurogentec
Integrated DNA Technology
Integrated DNA Technology
Integrated DNA Technology
50-FAM, 30-MGB Applied Biosystems
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PLA probes
PLA probe DARPin Target protein Oligonucleotide
Probe 1 SNAP_G3 HER2 Non-priming
Probe 2 G3_SNAP HER2 Priming
Probe 3 SNAP_9.01 HER2 Priming
Probe 4 SNAP_G3 HER2 Biovic 1
Probe 5 SNAP_9.01 HER2 biovic 2
PLA probe 50 modification Specific for Oligonucleotide
Probe 6 BC-maleimide CLIP-tag Priming
Probe 7 BG-hydrazine SNAP-tag Non-priming
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dimethylformamide (DMF); Covalys, Switzerland) in conjugation
buffer (100 mM MES, 150 mM NaCl, pH 4.8). The BG-modified
oligonucleotides were purified by reverse-phase high-performance
liquid chromatography (RP-HPLC) using a 4.6 mm  250 mm
silica matrix column with a particle size of 5 mm (Lichrosphere
RP18 column; Supelco. Inc.), a 60-min gradient of 2–60% B (A:
0.1 M triethylamine acetate (pH 7.0); B: acetonitrile) and a flow
rate of 1 mL/min. The reactive cysteine in the SNAP-tag-DARPin
fusion proteins (G3 and 9.01) were reduced in 20 mM DTT, and
incubated overnight at 48C in 1 mM DTT with a 3-fold molar excess
of BG-modified oligonucleotides, resulting in PLA probes G3-
SNAP-priming, non-priming-SNAP-G3, priming-SNAP-9.01, biovic1-
SNAP-G3 and biovic2-SNAP-9.01 (Table 2). No purifications of the
conjugates were undertaken, because remaining unconjugated
oligonucleotides were removed by washes in the in situ and solid
phase PLA reactions. The formation of conjugates was validated by
separating the products in a SDS polyacrylamide gel (GeneGel
Excel 12.5%; GE Healthcare), followed by protein silver staining
(PlusOneTM silver staining kit; GE Healthcare) (Fig. 1A), band
intensities were measured using Image J and the conjugation
efficiency was calculated via the intensity of the conjugate band
divided by the intensity of the non-conjugated SNAP-DARPin
band. The anti-HER2 antibody pertuzumab and the anti-HER2
polyclonal antibody (AF1129, R&D Systems) were conjugated
separately with aldehyde-modified priming and non-priming oligo-
nucleotides and with aldehyde-modified biovic 1 and biovic 2
oligonucleotides (Table 1), respectively, as previously described
[26]. In preparing probes for in situ analysis of FKBP and FRB
interaction, 50 mL of 100 mM thiol-modified priming oligonucleo-
tide was reduced in 20 mM DTT for 1 hour at 378C. The reduced
oligonucleotide was purified by MicroSpin G-50 column (GE
healthcare) and incubated for 2 hours at room temperature (RT)
with a 30-fold molar excess of BC-maleimide, followed by RP-
HPLC purification as described above. The preparation of non-
priming-BG was performed in the same way as for aldehyde-mod-
ified non-priming oligonucleotide (Table 2).
Cell cultures
The HER2 expressing breast cancer cell line (SK-BR-3) and ovarian
cancer cell line (SK-OV-3) were grown in RPMI1640 medium and the
human embryonic kidney cell line HEK 293T was grown in Dul-
becco’s modified Eagle’s medium (DMEM). All media were supple-
mented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and1% penicillin-streptomycin (all reagents from Sigma Aldrich). The
cells were grown at 378C in a humidified 5% CO2 environment.
Detection of HER2 in cells by in situ PLA
10,000 cells were seeded per well and cultivated overnight on Lab-
Tek Chamber Slides (Nalge Nunc International). Cells fixed in
EtOH were blocked in blocking buffer (1 mg/mL BSA, 20 mg/mL
salmon sperm DNA, 2 mM cysteine, 0.05% Tween20 in TBS buffer)
for 1 hour at 378C, followed by incubation with 40 mL of DARPin
PLA probes (non-priming-SNAP-G3 (2.4 nM) + G3-SNAP-priming
(2.4 nM), non-priming-SNAP-G3 (4.8 nM) + priming-SNAP-9.01
(23 nM), Table 2) diluted in blocking buffer ON at 48C. Circular-
ization oligonucleotide 1 and 2 (125 nM each, Table 1) in ligation
buffer (0.25 mg/mL BSA, T4 ligase buffer, 1 mM ATP, 250 mM NaCl,
0.05% Tween20, 0.05 U/mL T4 DNA ligase (Fermentas)) were incu-
bated at 378C for 30 min. After ligation rolling circle amplification
(RCA) was performed (0.25 mg/mL BSA, phi29 polymerase buffer,
0.25 mM dNTP, 0.125 U/mL phi29 polymerase (Thermo Scientific))
for 90 min at 37 8C followed by hybridization of 250 nM detection
oligonucleotide (Table 1) in detection buffer (2  SSC, 0.25 mg/mL
BSA, 75 ng/mL polyA, 0.05% Tween20) to the single-stranded RCA
product for 30 min at 378C. All steps were separated by two washes
in TBS + 0.05% Tween20 (TBST). The slides were counterstained
with DAPI (100 mg/mL) in Vectashield mounting medium (Vector
Laboratory). The same protocol was used for the pertuzumab PLA
probe (10 nM of each probe).
Detection of HER2 in cell lysate by solid-phase PLA
1.2  105 SK-BR-3 cells or HEK 293T cells were lysed in 150 mL cold
lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.5% Nonidet P-40, 0.5% Triton X-100, pH 7.4) supplemented with
a Complete Protease Inhibitor Cocktail Tablet (Roche). Tubes (Robo-
strip1, AJ Roboscreen) were coated with pertuzumab (1 ng/mL) in
carbonate buffer (50 mM Na2CO3, 50 mM NaHCO3, pH 9.6) for
1 hour at 378C. After blocking for 1 hour at 378C in PBS containing
1% BSA, 0.1% salmon sperm DNA and 0.05% Tween20, the tubes
were incubated with 50 mL of cell lysate at 48C ON. Subsequently,
50 mL of DARPin PLA probes (2 nM, biovic1-SNAP-G3 and biovic2-
SNAP-9.01) or anti-HER2 antibody PLA probes (1 nM) was added to
the tubes and incubated for 1.5 hours at 378C. All steps were
separated by three washes in PBS with 0.05% Tween20 (PBST).
Thereafter, 50 mL ligation and PCR mix (PCR buffer (Invitrogen)),
100 nM connector oligonucleotide (Table 1), 2.5 mM MgCl2, 0.4
units of T4 DNA ligase (Fermentas), 0.1 U uracil-DNA-glycosylase
(Fermentas), 80 mM ATP, 0.2 mM dNTPs containing dUTP, 0.1 mM
primers (fwdprimer and revprimer, Table 1), 220 nM Taqman probe
(Table 1) were added. The real-time PCR was performed in a Mx-
3000 instrument (Stratagene), with an initial incubation at 958C for
2 min, followed by 45 cycles of 958C for 15 s and 608C for 1 min.
Solid-phase PLA was also performed with lysate buffer alone as a
negative control. The results are presented as threshold cycle (Ct)
values [27], reflecting the amount of PLA ligation products, and as
DCt value where the Ct values for lysate buffer have been subtracted
from the Ct value for the cell lysate.
Detection of FKBP and FRB interaction
FKBP-SNAP and FRB-CLIP fusion encoding plasmids were co-trans-
fected together with a GFP-expressing vector and transientlywww.elsevier.com/locate/nbt 147
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2000 (Invitrogen) was carried out according to manufacturer’s
protocol using 2.5 mg of plasmid and 7.5 mL Lipofectamine and
incubation of 50 mL of plasmid-Lipofectamine complex for
24 hours. In this study, the FKBP-SNAP expressing plasmid
(1.125 mg) and the FRB-CLIP expressing plasmid (1.125 mg) were
co-transfected together with the GFP expressing vector (0.25 mg)
into HEK 293T cells. Thereafter, 15,000 cells/well were seeded on
collagen-type 1-coated slides (BD Biocoat) and cultivated for
4 hours. Rapamycin (dissolved in DMSO, Sigma–Aldrich) was
diluted in 200 mL of antibiotics-free growth medium to concen-
trations 0.2 mM, 1 mM, 5 mM, 20 mM and 40 mM and incubated with
cells for 6 hours at 378C in a humidified incubator with 5% CO2,
keeping the final concentration of DMSO at 0.1% (v/v). In parallel,FIGURE 2
Detection of HER2 in cells using DNA-modified DARPins and antibodies. (A) SDS-PAG
biovic 1 oligonucleotide, for production of a PLA probe (lane 2). Molecular weights 
protein silver staining, and the conjugation efficiency was estimated using Image J. (
different DARPins, one binding to domain IV (non-priming-SNAP-G3) and another on
to domain IV (non-priming-SNAP-G3 and G3-SNAP-priming) (middle panel), and pe
HER2 proteins. (C) Numbers of RCA products representing HER2 proteins in SK-OV-3
described in (B). Data were generated in triplicates and the quantification was perfo
and error bars indicate standard deviations.
148 www.elsevier.com/locate/nbt0.1% DMSO was included as a control for the effect of DMSO on
the FKBP/FRB interaction. Cells were then fixed in 3% parafor-
maldehyde (PFA) (Sigma–Aldrich) for 15 min at RT, permeabilized
for 15 min in 0.1% Triton X-100 (Sigma–Aldrich) in PBS, and
briefly washed in PBS. 20 nM of priming-BC and 20 nM non-prim-
ing-BG in PBS was applied to the cells and incubation for 1 hour at
378C was followed by 3 5 min washing in TBST. The in situ PLA
was performed as described above by steps of hybridization of
circularization oligonucleotides, RCA and detection.
Image analysis
Images of all cell experiments were taken in a Zeiss Axioplan II
epifluorescence microscope, using an AxioCam MRm CCD sensor
and a 40x/1.3 Oil PlanNeofluar objective together with filters forE gel demonstrating the conjugation of SNAP-9.01 (37.9 kDa) (lane 1) with the
of marker proteins (Fermentas) are shown in kDa. Proteins were visualized by
B) In situ PLA showing HER2 proteins in SK-OV-3 and HEK 293T cells using two
e binding to domain I (priming-SNAP-9.01) (left panel), both DARPins binding
rtuzumab PLA probes (right panel). Red dots are RCA products representing
 cells (white bars) and HEK 293T cells (grey bars) detected using in situ PLA, as
rmed in Duolink ImageTool (Olink Bioscience). Y-axis of the plot is in log scale
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digitally quantified using Duolink ImageTool (Olink Bioscience,
Sweden). For quantification of the number of PLA signals derived
from FKBP/FRB interactions, only cells displaying signals both in
the FITC channel (GFP transfected cells) and in the Cy3 channel
(from the RCA products) were counted digitally using the Duolink
ImageTool.
Results and discussion
Preparation of PLA probes using SNAP- and CLIP-tag technology
and verification by in situ and solid-phase PLA
Simple and efficient methods to attach DNA strands to recombi-
nant affinity proteins are needed to functionalize the reagents for
use in methods such as immuno-PCR and PLA [28]. Here, we
demonstrate a straightforward approach to convert recombinant
affinity reagents into PLA probes by using SNAP-tag fusions of
DARPin affinity reagents for site-specific and stoichiometrically
controlled conjugation of oligonucleotides. We wished to evaluate
if the reactivity of the 20 kDa SNAP and CLIP tags, engineered to
react covalently with benzyl-guanine or benzyl-cytosine deriva-
tives, could be exploited to attach oligonucleotides to proteins.
Two different approaches were used to obtain BG- (or BC-) deri-
vatized oligonucleotides. Aldehyde-oligonucleotide was first
coupled to hydrazine-BG and the product was purified via RP-
HPLC. An analogous reaction was also carried out between thiol-
modified oligonucleotide and the corresponding maleimide-BC
derivative. The BG-coupled oligonucleotides were then incubated
with DARPins fused to the SNAP domain tag, resulting in con-
jugates with a one-to-one ratio of oligonucleotides to affinity
reagents. In this manner, 75–85% of total DARPin-SNAP-tag fusion
proteins were successfully coupled to an oligonucleotide each, as
exemplified by the DARPin PLA probe shown in Fig. 2A. Because
the BG- and BC-modified oligonucleotides are stable for long
periods they can be prepared in large batches, facilitating DNAFIGURE 3
Comparison of HER2 detection in cell lysates using DARPins and antibody by solid-ph
DARPins, one binding to domain IV (biovic1-SNAP-G3), the other binding to domai
triangles), or polyclonal antibody against HER2 (in SK-BR-3 cell lysate, open circles; i
by subtracting the Ct value of lysis buffer from the Ct value of cell lysates (104 cells). 
dark grey bars. Mean values with standard deviations for triplicate measurementconjugation to many SNAP- or CLIP-labeled reagents. Two DAR-
Pins were used in these studies that both recognize the extracel-
lular part of the human HER2 membrane protein, frequently
overexpressed in, for example, breast cancer [29]. G3 has a KD
of about 100 pM to domain IV of HER2 [7,9], and 9.01 [8] binds
domain I with a KD of about 80 nM (C. Jost et al., unpublished).
Because it was not clear a priori whether the 20-kDa SNAP domain
might interfere with binding by the DARPin to HER2 on the cell,
constructs were prepared with the SNAP domain either at the N- or
C-termini of the DARPins. All products were obtained from E. coli
at the same high yield as unfused DARPins.
The HER2-specific DARPin-SNAP conjugates (PLA probes) were
applied for HER2 expression analyses both by in situ PLA (sche-
matic illustration of in situ PLA in Fig. 1A), and in solid-phase PLA
of cell lysates with quantitative PCR readout (schematic illustra-
tion of solid-phase PLA in Fig. 1B). When two different DARPins
are used to bind different epitopes of HER2, then both mono- and
dimeric HER2 can be detected, while with DARPins binding to the
same epitope (conjugated to different oligonucleotides), only
homo-dimeric or clustered forms of HER2 would be detected.
With HER2-overexpressing SK-OV-3 cells, the signals obtained
using two different DARPin-based PLA probes (referred to as
non-priming-SNAP-G3 and priming-SNAP-9.01) or only one DARPin
(non-priming-SNAP-G3 and G3-SNAP-priming) are about the same.
This suggests that most of the HER2 proteins are in a clustered state
on this cell line (Fig. 2B,C). Clustering of highly overexpressed
HER2 on tumor cells is consistent with previous observations [30].
Using pairs of PLA probes based on the therapeutic monoclonal
antibody pertuzumab, similar results were obtained (Fig. 2B,C). By
contrast, HEK 293T cells are known to express low but still mea-
surable amounts of HER2 [31]. In these cells, HER2 is not expected
to be oligomeric. Indeed, PLA signals were only seen when two
different DARPins were used (Fig. 2B,C), but not with only one
DARPin or with pertuzumab.ase PLA. (a) Performance of solid-phase PLA in cell lysates using two different
n I (biovic2-SNAP-9.01) (in SK-BR-3 cell lysate, filled circles; in HEK 293T, filled
n HEK 293T, open triangles). (b) Calculation of DCt from the data shown in (a)
Lysates from SK-BR-3 cells are shown in white bars and from HEK 293T cells in
s are shown.
www.elsevier.com/locate/nbt 149
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measurements in cell lysates by solid-phase PLA with quantita-
tive PCR readout. Here, HER2 levels in cell lysates from HER2
expressing SK-BR-3 cells and low HER2-expressing HEK 293T cells
were compared. HER2 proteins were captured by pertuzumab
immobilized on solid support and assayed using either two
different DARPin PLA probes, one binding to domain IV (bio-
vic1-SNAP-G3) and the other binding to domain I (biovic2-SNAP-
9.01), or an anti-HER2 polyclonal antibody divided in two ali-
quots, each conjugated to one of two different oligonucleotides.
Both experiments revealed the expected difference in levels of
HER2 proteins between the two lysates (Fig. 3). It should be
pointed out that the two DARPins used both recognize confor-
mational epitopes, and thus lysate preparations that even par-
tially denature HER2 risk decreasing assay sensitivity. TheFIGURE 4
In situ detection of rapamycin-mediated interactions between FKBP and FRB fusio
transfected with plasmids expressing FKBP-SNAP and FRB-CLIP fusion and with GFP
with treatment with 20 mM of rapamycin (B) for 6 hours. In situ PLA with PLA probe
FKBP and FRB fusion proteins in the absence and presence of rapamycin, and the
expressing cells (green). The cells were counterstained with DAPI (blue) to visualize t
expression in cells. (C) Bar graph demonstrating the frequency of cells with the ind
rapamycin in the culture media. On average 50 cells were investigated for each con
image analysis (Duolink ImageTool).
150 www.elsevier.com/locate/nbtpolyclonal anti-HER2 antibody (AF1129, RnD systems) that
was used in this assay, together with pertuzumab as capture
antibody on solid support, has been shown to detect HER2 in
Western blots and must thus be able to detect denatured forms of
HER2, or unfolded regions. The polyclonal antibody might
simultaneously bind different epitopes of HER2 and there may
be several oligonucleotides attached per antibody. By contrast,
the DARPins are monoclonal and strictly contain only one oli-
gonucleotide each, and will therefore produce less signals overall
than the antibody-based assay, both for lysates from SK-BR-3 cells
expressing high levels of HER2 and from HEK 293T cells (Fig. 3A).
The differences in HER2 detection signals between SK-BR-3 and
HEK 293T cells were similar, however, using the two classes of
affinity reagents (DCts of 6.4 and 6.7, for DARPins and antibodies
respectively) (Fig. 3B).n proteins via their fused SNAP and CLIP domains. HEK 293T cells were co-
-expressing plasmids. After 24 hours the cells were analyzed without (A) and
s (priming-BC and non-priming-BG) was applied for detection of interaction of
 RCA product detected with Alexa 555-labeled oligonucleotide (red) in GFP
he nuclei. GFP (green) served as an indicator of successful co-transfection and
icated numbers of RCA products (RCPs), as a function of the concentration of
centration of rapamycin in three experiments and analyzed using automated
New Biotechnology Volume 30, Number 2  January 2013 RESEARCH PAPER
R
es
ea
rc
h
P
ap
erIn situ conjugation of SNAP- and CLIP-fusion proteins
At times it is desirable to measure binding to and interactions
among proteins for which no suitable affinity reagents exist. We
investigated the possibility of transfecting cells with SNAP- and
CLIP-fusion gene constructs to study protein interactions with no
need for antibodies or any other specific protein-binding reagents.
We tested this strategy using FKBP and FRP as model system, as
interaction between these proteins can be induced by rapamycin.
Rapamycin binds with high affinity (KD = 0.2 nM) to the 12-kDa
FK506 binding protein (FKBP) as well as to a 100-amino acid
domain of the mammalian target of rapamycin (mTOR), known
as the FKBP-rapamycin binding domain (FRB), thereby forming a
FKBPrapamycinFRB ternary complex [32,33].
In cells transfected with SNAP- and CLIP-domains fused to FKBP
and FRB proteins, respectively, the fusion proteins were conju-
gated in situ with BG- and BC-modified DNA oligonucleotides.
Colocalization of the two oligonucleotides was investigated, by
addition of two connector oligonucleotides, capable of being
ligated into a DNA circle in reactions templated by the BG- and
BC-oligonucleotides. We demonstrated successfully circularized
oligonucleotides via RCA, followed by detection of the amplifica-
tion products using fluorophore-labeled oligonucleotides, com-
plementary to the repeated sequence of the RCA products. In the
absence of rapamycin, the transfected HEK 293T cells, expressing
FKBP-SNAP and FRB-CLIP, gave rise to only very few in situ PLA
reaction products (1–10 RCPs per cell) (Fig. 4A), whereas upon
incubation with 20 mM rapamycin the numbers of signals per cell
increased to greater than 100 per cell (Fig. 4B,C).
This approach provides a way to use in situ PLA where proteins of
interest can be expressed as fusion proteins with the SNAP or CLIP
domains after transfection. This strategy could also be combined
with the use of specific affinity reagents in situation where such a
reagent is only available against one partner in a protein interac-
tion. The procedure, which works on cells that have been fixed and
permeabilized, provides a complementary method to in situ inter-
action analysis of genetically modified living cells via Fo¨rsterresonance energy transfer (FRET) of pairs of fluorescent protein
domains that are expressed as fusions to the proteins of interest
[34,35] or by using complementing protein domains on fusion
proteins [36]. Although the in situ PLA approach, unlike FRET and
protein complementation techniques, is limited to fixed cells, the
strong signal amplification can be of value because it enables
detection of individual interaction events using standard micro-
scopy.
Conclusion
Because the reaction of BG- or BC-modified oligonucleotides with
SNAP or CLIP tags is a robust and specific procedure, this strategy
will be helpful to functionalize a large range of recombinant
affinity reagents for proteomics investigation through the addi-
tion of DNA strands. It thus provides a general means for produc-
tion of highly stable, renewable DNA-conjugated affinity reagents
with one oligonucleotide added in a site-specific fashion per
affinity reagent molecule. This was demonstrated for HER2-spe-
cific DARPin PLA probes. We also demonstrate that BG- and BC-
modified oligonucleotides can be used as general affinity reagents
directly in cells transfected with fusion gene constructs.
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